Orthomolecular Solutions to Heart Disease

[Guest guest]

http://www.newmediaexplorer.org/chris/2003/06/03/orthomolecular_solutions_to_hea\

rt_disease.htm

 

 

June 03, 2003

Orthomolecular Solutions to Heart DiseaseControl tactics

Practical Health

 

The following simple solution to prevent heart disease is currently ignored in

favour of paradigm of more invasive and lucrative disease management. Studying

the the data below, one could conclude that the eradication of the this disease

has been known for some time but is simply being ignored. This is an update to a

note I sent to a number of people who wanted to know about some inexpensive non

drug solutions. This note is by no means complete as I have not covered herbal

and other mineral adjuncts. So far - 5 people. that I know, have tired vitamin C

and Lysine and have had very good results.

 

Chris Gupta

 

This type of empowered and cost effective disease prevention is becoming a real

threat to the medical industry thus the CODEX initiative. Again, at the risk of

boring the reader, I direct you to the following link and encourage you to

educate as many people as possible on this imminent loss of safe health

solutions and our freedoms. http://www.iahf.com/anh_lawsuit.html

 

1) Linus Pauling Therapy for Heart Disease is at http://www.paulingtherapy.com/

and copiously describes a non toxic, cost effective Orthomolecular approach

using vitamin C and amino acids Lysine and Proline.

 

16] According to the Pauling/Rath 1994 United States patent, the amino acid

lysine (lysine analogs), along with vitamin C and other antioxidants (e.g.

Co-Q10, vitamin E and vitamin A), can, in sufficient concentration, inhibit

Lp(a) binding to exposed lysine residues. Proline residues are also exposed by

lesions in blood vessels. Later experiments showed that proline as well as

lysine, with vitamin C, other amino acids and antioxidants, in oral amounts well

past what is needed for prevention, becomes a solvent by inhibiting the binding

of Lp(a). A binding inhibitor augmented with vitamin C can stop and apparently

even reverses some plaque formations. Pauling and Rath even have a second U. S.

patent for using these binding inhibitors as solvents to melt atherosclerotic

plaques from human organs during organ transplants. The organ is dipped in the

Lp(a) Binding Inhibitor solution and the plaques melt away.

 

U. S. Patent # 5,278,189 is for the prevention and treatment of occlusive

cardiovascular disease with vitamin C and substances that inhibit the binding of

lipoprotein-(a).

 

See also patent 5,230,996 .

 

 

Backing this up with Vitamin B6 is described in the Joe Hattersley paper

" Vitamin B6: The overlooked Key to preventing heart attacks " More supporting

data in response to my earlier email also has been included at the end of this

note

 

ABSTRACT: Vitamin B6 (pyridoxine) opens the door to eliminating the 20th

century's epidemic of heart attacks, cardiac arrests and strokes. Although

shunned by the researchers who receive the bulk of heart disease research

funding, it is creating excitement among a growing number of investigators. In

this article relevant bits of B6's history are presented to show how it can

prevent heart attacks with almost no side effects from moderate amounts. This

article will also integrate the effects of vitamin B6 deficiency with Mathias

Rath and Linus Pauling's theory (blaming heart attacks on deficient vitamin C

and excess Lp(a) and Bruce Lipton's histamine theory into a general theory of

atherogenesis.

 

Vitamin B6 The overlooked Key to preventing heart attacks.PDF

 

As usual any effective products such as amino acids (mentioned below) which are

very effective for many diseases and essentially non toxic (far less toxic than

even salt) are banned illegally by Health Canada to protect their pharmaceutical

friends! So you will have get them from the states - 250 (500 mg) tablets of

lysine are available for approx $5 from US Walmart stores. The underground cost

in Canada is over $50 courtesy of Health Canada.

 

 

Chris Gupta

 

See also:

 

Reduction of Lipoprotein(a) in Postmenopausal Women

 

As a general surgeon who is interested in the prevention of postmenopausal heart

disease and in particular in the reduction of lipoprotein(a) [Lp(a)], I read

with great interest the recent review by Dr Mosca1 regarding the role of HRT.

Rapid progression of arteriographically determined coronary artery disease has

been significantly more common in subjects with Lp(a) levels higher than 25

mg/dL.2 Approximately 33% of the population have elevated levels of Lp(a) (>25

mg/dL), a condition that is an independent risk factor for coronary artery

disease.3, 4 The treatment currently recommended for postmenopausal women with

Lp(a) levels higher than 25 mg/dL consists of a combination of HRT and niacin.4

The adverse effects of niacin use are flushing, headache, and liver dysfunction.

I am a 53-year-old woman with a significantly elevated level of Lp(a) (27

mg/dL), but I found that I had to stop taking niacin primarily because of

headaches. Thus, after a thorough review of the literature, I

began to follow the advice of Linus Pauling. For individuals who have an Lp(a)

level higher than 25 mg/dL and a family history of heart disease, the

recommendation is to take 3 g/d of both ascorbic acid and L-lysine

monohydrochloride.5 After 6 months of this regimen, with no adverse effects, my

Lp(a) level decreased to 14 mg/dL, a reduction of 48%. The Lp(a) testing was

done by the highly reliable Lawrence Berkeley National Laboratory/Berkeley

HeartLab Department Technology Transfer program. The theory is that lysine is an

Lp(a)-binding inhibitor and thus blocks the Lp(a) attachment to the arterial

blood vessel wall and that ascorbic acid helps to repair the collagen injury to

the blood vessel and acts as an antioxidant.5-7 Currently, pilot studies are

being conducted on the Pauling therapy of elevated levels of Lp(a).

 

Kathie M. Dalessandri, MS, MD

Point Reyes Station, Calif

 

 

1. Mosca L. The role of hormone replacement therapy in the prevention of

postmenopausal heart disease. Arch Intern Med. 2000;60:2263-2272.

 

2. Terres W, Tatsis E, Pfalzer B, Beil FU, Beisiegel U, Hamm CW. Rapid

angiographic progression of coronary artery disease in patients with elevated

lipoprotein(a). Circulation. 1995;91:948-950. MEDLINE

 

3. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and

coronary heart disease in men aged 55 years and younger: a prospective study.

JAMA. 1996;276:544-548. MEDLINE

 

4. Superko HR. Did grandma give you heart disease? the new battle against

coronary artery disease. Am J Cardiol. 1998;82:34Q-46Q. MEDLINE

 

5. Pauling L, Rath M. Solution to the puzzle of human cardiovascular disease:

its primary cause is ascorbate deficiency leading to the deposition of

lipoprotein(a) and fibrinogen/fibrin in the vascular wall. J Orthomol Med.

1992;6:125-133.

 

6. Rath M, Pauling L. Hypothesis: lipoprotein(a) is a surrogate for ascorbate.

Proc Natl Acad Sci U S A. 1990;87:6204-6207. MEDLINE

 

7. Pauling L. The Last Interview [videotape]. Lisle, Ill: Intellisoft Multimedia

Inc; 1994.

 

(Arch Intern Med. March 12, 2001;161:772-773,)

 

Reduction of Lipoprotein(a) in Postmenopausal Women

http://archinte.ama-assn.org/issues/v161n5/ffull/ilt0312-4.html

 

In response to the above Joe wrote

JosephHattersley

Fri, 30 May 2003 13:18:52 EDT

Re: Orthomolecular Solutions to Heart Disease

 

Good work, Chris. On vitamin B6 why not add the info from trials:

 

(1) Thousands of people in East Texas took 50-300 milligrams of B6 daily for

many years under the guidance of John Marion Ellis, MD, of Mt. Pleasant, Texas.

He urged no change in the lives of patients suffering from carpal tunnel

syndrome and osteoarthritis -- those symptoms accurately portray high cardiac

risk -- except " Take vitamin B6. " Yet a retrospective study found his patients

had 73 percent fewer chest pains and heart attacks than thousands of ab-stainers

in the same area; they lived seven to 17 years longer; and they felt better.

Ellis JM, McCully KS. Prevention of myocardial infarction by vitamin B6.

Research Comm Molec Path and Pharmacol 1995; 89; 2:208-220.

 

(They -- and patients of Moses M. Suzman, MD, using B6 from 1950-1990 -- never

complained of over publicized neurological side effects. A few people may be

sensitive to this vitamin as pyridoxine hydrochloride, its common supplemented

form. Russell Jaffe, MD, PhD, eliminated neurological side effects among

thousands of volunteers by using pharmaceutical grade B6, 200 to 2,000

milligrams daily for up to two years. Lecture in Seattle, 1990. The product is

available from VRP 1-800-877-2447; 1-702-884-1300 www.vrp.com, and possibly from

others.)

 

(2) Among a sample of women followed for 20 years in the prospective Nurses'

Health Study, after adjustment for other risk factors heart attack risk dropped

17 percent for each two-milligram increase in daily B6 consumption in both diet

and supplements. Higher intakes yielded lower cardiac risk; an increase of eight

milligrams might then lower risk by 68%. Rimm EB, Willett WC et al. Folate and

vitamin B6 from diet and supplements in relation to risk of coronary heart

disease among women. Journal American Medical Assoc. 1998; 279; 5:359-364.

 

(3) In the 10-year ARIC (Atherosclerosis Risk in Communities) study, the people

in the highest quintile of plasma vitamin B6 had 72 percent fewer heart attacks

than those in the lowest quintile of plasma B6. As in Dr. Ellis's experience,

for non-cardiac patients nothing but B6 made any difference in cardiac risk -

not even now-famous homocysteine. Folsom AR, Nieto FJ et al. Prospective study

of coronary heart disease incidence in relation to fasting total homo-cysteine,

related genetic polymorphisms, and B vitamins. Circulation 1998; 98:204-210.

 

Moses M. Suzman, MD, of Johannesburg, South Africa, earlier confirmed that

finding with tens of thousands of patients over a period of forty years but did

not publish the results. Hattersley JG. Acquired atherosclerosis: Theories of

causation, novel therapies. Jour Orthomolecular Med 1991; 6:83-98. Derived from

50 telephone conversations and a 3-day stay at Dr. Suzman's home in

Johannesburg, April 1992, with several interviews.

 

The findings appear to confirm all the requirements for proof that vitamin B6

prevents heart attacks. Doll, Sir Richard. Proof of causality. Deduction from

epidemiological observation. Perspectives Biol Med 2002; 45; 4: 499-515

..

Cordially, Joe

 

See also: Bad News About Statin Drugs

 

 

 

Posted at June 3, 2003 12:00 AM | TrackBack

 

 

 

 

 

Finance: Get your refund fast by filing online